Blogs (12)

Asunercept (APG101) is a Selective CD95L Inhibitor for Glioblastoma Research

Asunercept (APG101) is a soluble CD95-Fc fusion protein targeting CD95L.
Efineptakin alfa (NT-17) is a Long-Acting Recombinant Human IL-7 for Glioblastoma Research

Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa can be used for glioblastoma research.
AZ31 is a Highly Selective and Orally Active ATM Inhibitor

AZ31 is a potent, highly selective, and orally active ATM inhibitor, and is also a potent radiosensitizer in vitro.
CP681301 is a Potent CDK5 Inhibitor

CP681301 is a potent CDK5 inhibitor, inhibits glioma stem cells self-renewal and shows anti-tumor activity.
NAZ2329 is an Allosteric Inhibitor of R5 RPTP Subfamily and PTPRZ/PTPRG

NAZ2329 is an allosteric, noncompetitive and reversible inhibitor of R5 RPTP subfamily and PTPRZ/PTPRG with anti-cancer activity.
PINT87aa, a Potential Tumor-Suppressive Peptide, Directly Interacts with the PAF1 Complex

PINT87aa, a potential tumor-suppressive peptide, directly interacts with the PAF1 complex and inhibits mRNA transcriptional elongation.
RapaLink-1, a Third-Generation Bivalent mTOR Inhibitor, Combines Rapamycin with MLN0128

RapaLink-1, a third-generation bivalent mTOR inhibitor, potently blocking cancer-derived, activating mutants of mTOR. It can cross the blood-brain barrier.
AMG-458 is a Selective and Orally Bioavailable c-Met Inhibitor

AMG-458 is a potent, selective and orally bioavailable c-Met inhibitor with potent anti-tumor activity in the NIH3T3/TPR-Met and U-87 MG xenograft models.
JCN037 is a Non-Covalent and Brain-Penetrant EGFR Inhibitor

JCN037 is a potent, non-covalent, and brain-penetrant EGFR tyrosine kinase inhibitor. JCN037 has potent anti-cancer activity.
TCH-165, a Proteasome Assembly Modulator, Regulates the Dynamic Equilibrium between the 20S and 26S Proteasome Complexes

TCH-165 is a modulator of proteasome assembly, which increases 20S levels and facilitates 20S-mediated protein degradation, such as IDPs, α-syn, and tau.

Name
Email *

	Sorry, but the email address you supplied was invalid.